NASDAQ:URGN
UroGen Pharma Ltd Stock News
$14.26
+0.0200 (+0.140%)
At Close: Apr 18, 2024
Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates
05:25pm, Monday, 15'th Nov 2021 Zacks Investment Research
Urogen Pharma (URGN) delivered earnings and revenue surprises of -7.14% and -28.61%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates
01:55pm, Monday, 15'th Nov 2021
Urogen Pharma (URGN) delivered earnings and revenue surprises of -7.14% and -28.61%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q3 2021 Results - Earnings Call Transcript
01:19pm, Monday, 15'th Nov 2021
UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q3 2021 Results - Earnings Call Transcript
UroGen Pharma EPS misses by $0.06, misses on revenue
01:09pm, Monday, 15'th Nov 2021 Seeking Alpha
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
02:57pm, Sunday, 14'th Nov 2021 Benzinga
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences.
Among the
Earnings Preview: UroGen Pharma
11:02am, Friday, 12'th Nov 2021
UroGen Pharma (NASDAQ:URGN) is set to give its latest quarterly earnings report on Monday, 2021-11-15. Here's what investors need to know before the announcement.
UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q2 2021 Results - Earnings Call Transcript
07:50am, Saturday, 07'th Aug 2021
UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q2 2021 Results - Earnings Call Transcript
UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2021 Results - Earnings Call Transcript
01:52pm, Thursday, 13'th May 2021
UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2021 Results - Earnings Call Transcript
UroGen Pharma Reports First Quarter 2021 Financial Results and Recent Corporate Developments
07:30am, Thursday, 13'th May 2021
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic dis
UroGen Pharma Ltd.'s (URGN) CEO Liz Barrett on Q4 2020 Results - Earnings Call Transcript
01:54pm, Thursday, 18'th Mar 2021
UroGen Pharma Ltd.'s (URGN) CEO Liz Barrett on Q4 2020 Results - Earnings Call Transcript
UROGEN PHARMA (URGN) Reports Q4 Loss, Tops Revenue Estimates
10:13am, Thursday, 18'th Mar 2021
UROGEN PHARMA (URGN) delivered earnings and revenue surprises of -5.34% and 10.46%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
UroGen Pharma: Q4 Earnings Insights
08:17am, Thursday, 18'th Mar 2021
Shares of UroGen Pharma (NASDAQ:URGN) rose 3.6% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 25.81% year over year to ($1.38), which miss
UroGen Pharma Announces $75 Million of Non-Dilutive Funding from RTW Investments
07:30am, Thursday, 18'th Mar 2021
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic dis
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic dis
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 05'th Mar 2021
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic dise
